Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Apr-May;13(4-5):367-71.
doi: 10.1016/j.autrev.2014.01.022. Epub 2014 Jan 11.

Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review

Affiliations
Review

Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review

Michael Mahler et al. Autoimmun Rev. 2014 Apr-May.

Abstract

Autoantibodies are a hallmark in the diagnosis of many systemic autoimmune rheumatic diseases (SARD) including idiopathic inflammatory myopathies (IIM). Based on their specificity, autoantibodies in IIM are grouped into myositis specific (MSA) and myositis associated autoantibodies (MAA). Among the MSA, autoantibodies against aminoacyl-tRNA synthetases (ARS) represent the most common antibodies and can be detected in 25-35% of patients. The presence of ARS and other autoantibodies has become a key feature for classification and diagnosis of IIM and is increasingly used to define clinically distinguishable IIM subsets. For example, anti-ARS autoantibodies are the key features of what has become known as anti-synthetase syndrome (aSS), characterized by multiple organ involvement, primarily interstitial lung disease, often accompanied by myositis, non-erosive arthritis, Raynaud's phenomenon, fever, and "mechanic's hands". Autoantibodies directed to eight different ARS have been described: Jo-1 (histidyl), PL-7 (threonyl), PL-12 (alanyl), OJ (isoleucyl), EJ (glycyl), KS (asparaginyl), Zo (phenylalanyl) and Ha (tyrosyl). Each anti-ARS antibody seems to define a distinctive clinical phenotype. Although several research methods and commercial tests are available, routine testing for anti-ARS autoantibodies (other than anti-Jo-1/histidyl-tRNA synthetase) is not widely available, sometimes leading to delays in diagnosis and poor disease outcomes.

Keywords: Autoantibodies; Immunoassay; Jo-1; Myositis; Synthetase.

PubMed Disclaimer

Conflict of interest statement

Competing interests

M. Mahler, is employed at INOVA Diagnostics a manufacturer of autoantibody kits and assays. M.J. Fritzler is a paid consultant of ImmunoConcepts Inc. and INOVA Diagnostics and has received diagnostics gifts in kind from Euroimmun.

Figures

Figure 1
Figure 1
Detection of anti-ARS autoantibodies. A.) The classical indirect immunofluorescence (IIF) pattern of an anti-Jo-1 autoantibody positive sample is characterized by diffuse cytoplasmic staining on HEp-2 cells. Autoantibodies to other synthetases can show similar staining patterns. To differentiate the pattern from other cytoplasmic patterns (i.e. anti-ribososmal P autoantibodies), the absence of nucleolar staining is an important discriminator. It should be noted that less than half of the sera that have identifiable anti-Jo-1 will demonstrate this typical IIF pattern. The specific proteins identifying each autoantibody are marked with triangles. B.) Characterization of various anti-ARS autoantibodies (anti-Jo-1, PL-7, PL-12, OJ, EJ) by protein immunoprecipitation using 35S-methionine-labeled K562 cell lysates, SDS-PAGE and autoradiography is shown (courtesy of Dr. Minoru Satoh). C.) Immunoprecipitation profile of cytoplasmic RNAs using phenol/chloroform extraction and urea-PAGE followed by silver staining demonstrating the typical tRNAs associated with each of the anti-ARS autoantibodies (courtesy of Dr. Minoru Satoh).

References

    1. Mammen AL. Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis. Nat Rev Neurol. 2011;7:343–354. - PubMed
    1. Betteridge ZE, Gunawardena H, McHugh NJ. Novel autoantibodies and clinical phenotypes in adult and juvenile myositis. Arthritis Res Ther. 2011;13:209. - PMC - PubMed
    1. Rider LG, Shah M, Mamyrova G, Huber AM, Rice MM, Targoff IN, et al. The Myositis Autoantibody Phenotypes of the Juvenile Idiopathic Inflammatory Myopathies. Medicine (Baltimore ) 2013;92:223–243. - PMC - PubMed
    1. Ghirardello A, Bassi N, Palma L, Borella E, Domeneghetti M, Punzi L, et al. Autoantibodies in polymyositis and dermatomyositis. Curr Rheumatol Rep. 2013;15:335–0335. - PubMed
    1. Koenig M, Fritzler MJ, Targoff IN, Troyanov Y, Senecal JL. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther. 2007;9:R78. - PMC - PubMed

Publication types

Supplementary concepts